Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05212467
Other study ID # HUS/2239/2021
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 31, 2022
Est. completion date December 31, 2024

Study information

Verified date January 2022
Source Helsinki University Central Hospital
Contact Helena Liira, MD, PhD
Phone +358 50 577 1351
Email helena.liira@hus.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare an Amygdala and insula retraining (AIR) program to an internet therapy developed at Helsinki University Hospital. The study will be a multi-center randomized controlled trial. Study units will be recruited from the Network for Functional Disorders that is hosted by the HUS Clinic for Functional Disorders and potentially later from international collaborators. The trial will clarify whether internet-based non-drug based therapies are helpful in overcoming the central sensitization and the functional disabilities caused by these disorders.


Description:

Functional disorders are a challenging group of conditions treated both in primary and secondary care. Recently, mounting evidence shows that central nervous system sensitization is one of the involved mechanisms, giving new treatment opportunities. There are self-management programs and internet therapies that aim at overcoming the central sensitization by creating new neural networks in the brain. This study aims to test whether an Amygdala and insula retraining (AIR) program compared to an internet therapy developed at HUS (Helsinki University Hospital) and treatment as usual (TAU) is effective in the treatment of functional disorders, fibromyalgia, long Covid, and chronic fatigue syndrome (ME/CFS). The investigators will perform a multi-center randomized controlled trial in volunteering health units and with volunteering patients aiming at 360 patients altogether. The physicians in charge of the patients will be recruited from the Network for Functional Disorders launched by the novel clinic at HUS. The participating centers will receive an introduction in functional disorders, the underlying mechanisms, and treatment opportunities. For functional disorders, this study applies the ICD-11 primary care code of Bodily stress syndromes (BSS), which covers fibromyalgia, irritable bowel syndrome, multiple chemical sensitivities, and other, both single system and multiorgan functional disorders. In addition, for patients with fibromyalgia, chronic fatigue symptoms, and Post Covid-19 condition, we will apply specific diagnostic criteria. Both primary and secondary care treatment units that manage these disorders can recruit patients. The studied interventions are an Amygdala and insula retraining (AIR) program and an internet therapy developed at HUS, and patients receive usual care in addition to these interventions. The third study arm consists of treatment as usual for six months after which the patients receive the AIR program or the internet therapy if they so wish. When the participating physicians consider that a patient could benefit from a self-management program, they introduce the trial to the patient. The consenting patient fills in a baseline survey and is followed up at 3, 6, and 12 months with the help of the HUSeCRF (online surveys at the HUS electronic Case Report Form), or research nurse's interviews. This study will give new insight into the opportunities of self-management programs in the treatment of bodily stress syndromes, fibromyalgia, Post Covid-19, and ME/CFS. The investigators will find out whether the training programs increase patients' functional ability and quality of life as measured on a scale from 0 to 10. These scales and functional ability as measured by WHODAS 2.0 serve as main outcome measures for this study. This trial is the first large-scale randomized trial that assesses these methods developed to overcome the central sensitization of brain. The results will have an impact on the management of these common and often debilitating conditions.


Recruitment information / eligibility

Status Recruiting
Enrollment 360
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - • The criteria of bodily stress syndrome, fibromyalgia, chronic fatigue syndrome, or long Covid fulfilled AND - Diagnostic examinations have ruled out the potential somatic reasons for the symptoms AND - Disabling symptoms have lasted at least 3 months AND - Patient is willing to receive a psychoeducation or brain retraining intervention. Exclusion Criteria: - • Patients for whom participation could be overly demanding because of physical constraints (for example, patients who cannot write because of dystonia or bedridden patients) - Patients with presence of severe psychiatric and severe somatic disorders, e.g. moderate or severe depression or newly onset cancer for which the study could be overly strenuous.

Study Design


Intervention

Behavioral:
AIR-program
This is a guided self management program that is added on the treatment as usual.
HUS Internet therapy
This is a guided self management program that is added on the treatment as usual.
Treatment as usual
The patients receive routine care from their physician which may include drugs, visits or rehabilitation

Locations

Country Name City State
Finland Clinic for Functional Disorders, HUS Helsinki
Finland Clinic for Long Covid, HUS Helsinki

Sponsors (1)

Lead Sponsor Collaborator
Helsinki University Central Hospital

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in functional ability as measured by the WHODAS2.0 instrument at six months. 3, 6 and 12 months
Secondary Change from baseline in quality of life as measured by EUROHIS-8 3, 6 and 12 months
Secondary Change from baseline in health related quality of life as measured by 15D 3, 6 and 12 months
Secondary Change from baseline in symptoms as measured by SSD-12 and PHQ-15 3, 6 and 12 months
Secondary Change from baseline in depression as measured by PHQ-9 3, 6 and 12 months
Secondary Change from baseline in anxiety as measured by GAD-7 3, 6 and 12 months
Secondary Change in sleep as measured by ISI 3, 6 and 12 months
Secondary Change in resilience as measured by Resilience Scale-14 3, 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04544605 - Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients
Completed NCT05447039 - Value of Montelukast as a Potential Treatment of Post COVID-19 Persistent Cough N/A
Completed NCT05225220 - Multimodal Investigation of Post COVID-19 in Females N/A
Recruiting NCT05175807 - A Telemedicine Brief Mindfulness Intervention in Post-COVID-19 N/A
Recruiting NCT05371925 - Endothelial Protection in Post COVID-19 Patients With Sulodexide Phase 3
Completed NCT04574050 - SELF-BREATHE RCT for Chronic Breathlessness N/A
Active, not recruiting NCT05298878 - Virtual Physical Rehabilitation for Patients Living With Long COVID N/A
Active, not recruiting NCT05282043 - Pulmonary and Extrapulmonary Impacts of COVID-19 on Young Adults N/A